Rigel Pharmaceuticals’s recent filing unveils that its EVP & Chief Financial Officer Schorno Dean L unloaded Company’s shares for reported $42595.0 on Feb 04 ’25. In the deal valued at $20.92 per share,2,036 shares were sold. As a result of this transaction, Schorno Dean L now holds 58,969 shares worth roughly $1.43 million.
Then, Schorno Dean L sold 1,734 shares, generating $38,020 in total proceeds. Upon selling the shares at $21.93, the EVP & Chief Financial Officer now owns 57,235 shares.
Before that, Santos David A sold 2,125 shares. Rigel Pharmaceuticals shares valued at $44,457 were divested by the EVP, Chief Commercial Officer at a price of $20.92 per share. As a result of the transaction, Santos David A now holds 53,500 shares, worth roughly $1.3 million.
A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early June from “a Buy” to “a Neutral”. Piper Sandler also remained covering RIGL and has decreased its forecast on June 08, 2022 with a “Neutral” recommendation from previously “an Overweight” rating. Cantor Fitzgerald revised its rating on June 08, 2022. It rated RIGL as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of RIGL
On Tuesday, Rigel Pharmaceuticals [NASDAQ:RIGL] saw its stock jump 6.93% to $24.24. Over the last five days, the stock has gained 21.81%. Rigel Pharmaceuticals shares have risen nearly 141.67% since the year began. Nevertheless, the stocks have risen 44.11% over the past one year.
How much short interest is there in Rigel Pharmaceuticals?
A steep rise in short interest was recorded in Rigel Pharmaceuticals stocks on 2025-07-15, growing by 0.3 million shares to a total of 2.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.1 million shares. There was a rise of 12.35%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 23, 2022 when B. Riley Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $4 price target.
